|
|
Article: Phase II Studies Show Investigational Insomnia Agent Gaboxadol Improved Deep Sleep and Key Sleep Measures in Adults with Primary and Transient Insomnia.
- Article from:
- Business Wire
- Article date:
- June 21, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SALT LAKE CITY -- Results from phase II studies presented this week demonstrated the effects of gaboxadol on sleep architecture (visual polysomnograph and computerized analysis of the waveform through the stages of sleep) in both primary and transient insomnia. In a model of transient insomnia the traditional measures of sleep onset and maintenance were also reported. Gaboxadol, an investigational agent under clinical development by Merck & Co., Inc. and H. Lundbeck A/S for the treatment of insomnia, is a first-in-class selective extrasynaptic GABA(A) receptor agonist (SEGA). The data were presented at the SLEEP 20th Anniversary Meeting of the Associated Professional ...